PSMA靶向18F-DCFBC PET/CT显像对根治性局部治疗后生化复发前列腺癌患者的临床影响
这项前瞻性研究纳入68例根治性局部治疗后生化复发且常规影像阴性的前列腺癌患者,行全身18F-DCFBC PET/CT(62例另在1个月内行mpMRI)。41例(60.3%)检出至少1个阳性病灶;PSA≥0.78 ng/mL时预测阳性扫描的AUC=0.764;阳性结果使51.2%(21/41)患者的临床管理发生改变。
要点
- 68例生化复发前列腺癌患者中41例(60.3%)18F-DCFBC PET/CT检出阳性病灶,共79个。
- 预测阳性扫描的最佳PSA阈值为0.78 ng/mL(AUC=0.764)。
- 18F-DCFBC阳性者中51.2%(21/41)临床管理改变,多为启动新治疗。
核心结论
- 18F-DCFBC在生化复发人群中检出60.3%的复发灶,但结果依赖PSA水平。
- PSA高于阈值0.78 ng/mL时,18F-DCFBC能高可靠性地识别复发。
- 18F-DCFBC PET阳性使51.2%的患者治疗策略发生改变。
研究设计与样本
- 前瞻性、经IRB批准的研究,纳入68例原发性局部治疗(根治性前列腺切除术n=50、放疗后n=9、两者兼有n=9)后记录到生化复发且常规影像阴性的患者。
- 全部68例行全身18F-DCFBC PET/CT,其中62例在1个月内另行mpMRI。
- 将18F-DCFBC病灶检出与mpMRI结果及扫描前PSA水平进行相关性分析,并在6个月临床随访后评估其对临床管理和治疗决策的影响。
主要发现
- 41例(60.3%)显示至少一个18F-DCFBC阳性病灶,共79个病灶:前列腺床30个、淋巴结39个、远处部位10个。
- 肿瘤复发经活检(13/41例)、系列CT/MRI(8/41)或临床随访(15/41)确认,5例未获确认并继续观察。
- 18F-DCFBC与mpMRI结果一致39个病灶(49.4%)、不一致40个病灶(50.6%),不一致中的多数(32/40)因复发位于mpMRI视野之外。
- PSA<0.5、0.5至<1.0、1.0至<2.0、≥2.0 ng/mL患者的18F-DCFBC PET阳性率分别为15%、46%、83%、77%。
- 预测18F-DCFBC阳性扫描的最佳PSA cut-off值为0.78 ng/mL(AUC=0.764)。
关键数值与推荐
- 预测阳性18F-DCFBC扫描的最佳PSA cut-off值为0.78 ng/mL(AUC=0.764)。
- PSA<0.5 ng/mL者18F-DCFBC PET阳性率为15%,0.5至<1.0 ng/mL者为46%,1.0至<2.0 ng/mL者为83%,≥2.0 ng/mL者为77%。
- 18F-DCFBC与mpMRI结果一致39个病灶(49.4%),不一致40个病灶(50.6%)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The purpose of our study was to assess 18F-DCFBC PET/CT, a PSMA targeted PET agent, for lesion detection and clinical management of biochemical relapse in prostate cancer patients after primary treatment. METHODS: This is a prospective IRB-approved study of 68 patients with documented biochemical recurrence after primary local therapy consisting of radical prostatectomy (n = 50), post radiation therapy (n = 9) or both (n = 9), with negative conventional imaging. All 68 patients underwent whole-body 18F-DCFBC PET/CT, and 62 also underwent mpMRI within one month. Lesion detection with 18F-DCFBC was correlated with mpMRI findings and pre-scan PSA levels. The impact of 18F-DCFBC PET/CT on clinical management and treatment decisions was established after 6 months' patient clinical follow-up. RESULTS: Forty-one patients (60.3%) showed at least one positive 18F-DCFBC lesion, for a total of 79 lesions, 30 in the prostate bed, 39 in lymph nodes, and ten in distant sites. Tumor recurrence was confirmed by either biopsy (13/41 pts), serial CT/MRI (8/41) or clinical follow-up (15/41); there was no confirmation in five patients, who continue to be observed. The 18F-DCFBC and mpMRI findings were concordant in 39 lesions (49.4%), and discordant in 40 lesions (50.6%); the majority (n = 32/40) of the latter occurring because the recurrence was located outside the mpMRI field of view. 18F-DCFBC PET positivity rates correlated with PSA values and 15%, 46%, 83%, and 77% were seen in patients with PSA values <0.5, 0.5 to <1.0, 1.0 to <2.0, and ≥2.0 ng/mL, respectively. The optimal cut-off PSA value to predict a positive 18F-DCFBC scan was 0.78 ng/mL (AUC = 0.764). A change in clinical management occurred in 51.2% (21/41) of patients with a positive 18F-DCFBC result, generally characterized by starting a new treatment in 19 patients or changing the treatment plan in two patients. CONCLUSIONS: 18F-DCFBC detects recurrences in 60.3% of a population of patients with biochemical recurrence, but results are dependent on PSA levels. Above a threshold PSA value of 0.78 ng/mL, 18F-DCFBC was able to identify recurrence with high reliability. Positive 18F-DCFBC PET imaging led clinicians to change treatment strategy in 51.2% of patients.
引用
- Mena E, Lindenberg ML, Shih JH, et al. Clinical impact of PSMA-based 18F-DCFBC PET/CT imaging in patients with biochemically recurrent prostate cancer after primary local therapy. Eur J Nucl Med Mol Imaging. 2017. PMID: 28894899. doi:10.1007/s00259-017-3818-x
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。